30 Jun 2017 To date, Abaxis' Piccolo is the only point-of-care technology that can deliver comprehensive ABAXIS, Inc. (ABAX): Free Stock Analysis Report. 6 Aug 2019 Taylor served as CFO at Abaxis, Inc. (Nasdaq: ABAX) from 2015 through the sale of the company to Zoetis in July 2018 . Abaxis was a diagnostic 16 May 2018 Animal health company Zoetis said it would buy Abaxis, a maker of veterinary The stock has surged 45 percent since the start of the year. 15 Jan 2016 Abaxis, Inc. (ABAX) has experienced a stock price decline of 12.6% during the last four quarters. Abaxis, which manufactures medical
At Abaxis our mission is to supply point of care blood analyzers to the medical market and the veterinarian market. Abaxis provides leading edge technology, tools and services that support best medical practices, enabling physicians and veterinarians to respond to the health needs of their clients at the point of care while operating economical and profitable practices. Check out our ABAX stock analysis, current ABAX quote, charts, and historical prices for Abaxis Inc stock Shares of Abaxis, Inc. ABAX skyrocketed soon after its acquisition news grabbed headlines. The stock jumped more than 16% yesterday following animal.
Here comes the data for ABAXIS Inc (ABAX). In the 52 weeks ending on 2018-08-01 the highest price reached by ABAXIS Inc (ABAX) stock was 83.5384. The lowest price was 43.4775. The daily prices are volatile. Hence, the highest one day price may be misleading. Hence some prefer looking at weekly and monthly averages (highest and lowest averages). Abaxis, Inc (ABAX) Stock Dividend Data. ABAX Stock Dividend Data. Dividend Yield Dividend Yield. Dividend yield is the relation between a stock’s annual dividend payout and its current stock price. Click here to learn more. 0.00% healthcare Average 0.00% ANNUALIZED PAYOUT Annualized Payout. Abaxis Inc Stock Upgraded (ABAX) Abaxis (Nasdaq:ABAX) ABAXIS INC's earnings per share declined by 43.3% in the most recent quarter compared to the same quarter a year ago. FINANCIAL BRIEF:: For the fiscal year ended 31 March 2018, Abaxis Inc revenues increased 8% to $244.7M.Net income before extraordinary items decreased 6% to $30.7M. Revenues reflect Veterinary Market segment increase of 8% to $201.9M, Medical Market segment increase of 5% to $38.6M, North America segment increase of 7% to $194.7M, Europe segment increase of 10% to $36.2M. Abaxis, Inc. (Nasdaq: ABAX) Abaxis shareholders will receive only $83.00 in cash for each share of Abaxis stock they own. The investigation concerns whether the Board of Abaxis breached their fiduciary duties to shareholders and whether Zoetis is underpaying for the Company. Abaxis, Inc. | 5,614 followers on LinkedIn | Abaxis is a leader in the development and commercialization of leading-edge medical device and innovative technology and services that support best